#Florida Cancer Specialists #Oncology Care #Maen Hussein

Florida Cancer Specialists Appoints Dr. Maen Hussein

Florida Cancer Specialists & Research Institute (FCS) has recently announced a significant addition to its team, appointing Dr. Maen Hussein as the new Medical Director of Value-Based Care. Dr. Hussein, a seasoned medical oncologist and hematologist, has been a key member of FCS since 2011 and has been providing exemplary care to patients at the FCS Villages Cancer Center and the FCS Brownwood location. His extensive experience in oncology makes him an excellent choice to oversee the development and implementation of initiatives that prioritize patient-centered care, all while managing costs efficiently.

Dr. Hussein's new role is crucial as the healthcare industry evolves towards value-based care, which emphasizes patient outcomes rather than the quantity of services provided. In his position, Dr. Hussein will be responsible for overseeing ongoing projects that aim to enhance the quality of oncology services offered by FCS, ensuring that they remain at the forefront of innovative and effective patient care.

Lucio N. Gordan, MD, the president and managing physician of FCS, commended Dr. Hussein's clinical skills and leadership abilities, stating that his appointment will drive innovation and collaboration within FCS and its partnerships. This leadership change reflects FCS's ongoing commitment to delivering high-quality, cost-effective care that prioritizes the well-being of cancer patients across the state.

FCS has positioned itself as a leader in value-based oncology care, recognized as a top-performing participant in the Oncology Care Model (OCM), which is sponsored by the Centers for Medicare and Medicaid Innovation. The institution has successfully established various value-based initiatives, partnering with commercial payers, Accountable Care Organizations (ACOs), and Managed Service Organizations (MSOs) to drive improvements in care delivery and patient outcomes.

Among the noteworthy advances at FCS is the recent launch of the Holistic Model of Care. This pioneering program is comprehensive and inclusive, catering to all patients regardless of their healthcare coverage. Patients enrolled in this program can expect a robust support system that includes not only physicians but also nurse navigators, behavioral health specialists, and nutritionists, all working collaboratively to provide the best standard of care.

Nathan H. Walcker, CEO of FCS, expressed his excitement about this newly created role, emphasizing the organization's fundamental commitment to patient-centric initiatives. The goal is to ensure that value-based care remains effective into the future, leveraging clinical expertise, advanced technology platforms, and data analytics to enhance service quality while managing costs.

Dr. Hussein's dedication to cancer research and advocacy is also noteworthy. He has served as a principal investigator in numerous clinical trials, particularly focusing on lung cancer. His research contributions have been recognized at various prestigious industry events, and he currently presides over the Florida Society of Clinical Oncology (FLASCO) board of directors.

FCS has built a national reputation since its founding in 1984, arising from its commitment to exceptional patient care, innovative clinical research, and the provision of cutting-edge treatments, including immunotherapy and genomic-based therapy. The organization stands as the largest provider of clinical trials in Florida's private oncology sector and holds an outstanding track record of being recognized among the